BIIB Jun 2023 285.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 11:15AM EDT. Market open.
Loading interactive chart…
- Simply Wall St.
Biogen Inc. (NASDAQ:BIIB) is a favorite amongst institutional investors who own 88%
Key Insights Given the large stake in the stock by institutions, Biogen's stock price might be vulnerable to their...
- Zacks
Biotech Stock Roundup: ALT Obesity Data, GILD Exercises Option, INCY Drug Approval
Incyte's (INCY) skin cancer drug approval and Altimmune's obesity data are the key highlights from the biotech sector during the past week.
- Zacks
Biogen (BIIB) Gets Positive FDA Panel Vote for Tofersen NDA
The FDA committee supports an accelerated approval of Biogen's (BIIB) tofersen for treating SOD1-ALS. The committee does not believe the data supports a traditional/standard approval for tofersen.
© 2023 Yahoo. All rights reserved.
